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TREATMENT CONTINGENT UPON ETIOLOGY:
TWO ADULT FEMALE PATIENTS WITH MILD INTELLECTUAL DISABILITY 
AND A CAUSATIVE COPY NUMBER VARIATION
Willem M.A. Verhoeven, Jos I.M.Egger, Nicole de Leeuw and Tjitske Kleefstra
Abstract
Objective: While modern genetic techniques have substantially increased the knowledge regarding causes of 
intellectual disabilities and related neuropsychiatric disorders, a marked time-lag can be noticed with respect to its 
implementation in common psychiatric practice. Given the relatively strong emphasis on diagnostic classification to 
the disadvantage of phenomenological and etiopathophysiological factors, the application of etiology-based treatment 
strategies may be seriously hindered. This a fortiori holds for patients with mild intellectual disability in the absence of 
salient dysmorphic features or congenital anomalies. 
Method: The present paper illustrates this by means of two adult female patients with mild intellectual disability and 
late onset of symptoms from the mood and cognitive spectra. 
Results and conclusions: In both patients microarray analysis disclosed de novo copy number variations, being 
a 2.05 Mb mosaic interstitial deletion in 7p21.1p15.3 in patient A and a 1.48 Mb interstitial duplication in 17q12 in 
patient B. These findings led to an appropriate diagnosis and gave direction to a significant change in treatment that 
resulted in an improvement of general functioning.
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Introduction
Over the past decades, the introduction of modern 
genetic techniques like genomic microarray and whole 
exome sequencing has led to the discovery of several de novo 
copy number variations (CNV) and mutations providing 
support for their causative nature in developmental delay 
and intellectual disability (Vissers et al. 2010, de Ligt et 
al. 2012, Gilissen et al. 2014, Athanasakis et al. 2014, 
Martinez et al. 2017). Because of the substantially high 
prevalence of challenging behaviours in neuropsychiatric 
patients, whether or not associated with intellectual 
disability, the application of these techniques is of vital 
importance for the understanding of the disease and its 
etiology-guided treatment (Vulto-van Silfhout et al. 2013, 
McRae et al. 2017). 
Since current psychiatric consultation is increasingly 
restricted to the inventory of symptoms as categorised in 
diagnostic classification systems, in this process, often, 
the detailed analysis of course and history including 
neurocognitive and social-emotional development is 
neglected. In this way, the importance of a psychiatric 
diagnosis can be easily overestimated which, in turn, 
may cloud important etiological factors and increase 
the risk of erroneous treatment decisions (Verhoeven 
and Egger 2014). 
In this paper, two adult female patients with mild 
intellectual disability are described who, for the first 
time, developed psychiatric and cognitive symptoms 
around the start of their third decade. 
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regional institute for social-pedagogic services, 
primarily for evaluation of her cognitive and social-
emotional functioning. She was born from non-
consanguineous parents after an uncomplicated 
pregnancy and has two older healthy brothers. There 
was no family load with intellectual disabilities or 
neuropsychiatric diseases. Her history showed a slight 
delay of all milestones. After having completed primary 
school, the patient followed special education until 
the age of 20 years. Over subsequent years she was 
employed at a sheltered home facility while staying at her 
parents’ home. Sixteen years later, while considering to 
leave her parental home, she was examined for the first 
time. A healthy woman was seen with a height, weight 
and head circumference of 155cm, 70kg and 49cm, 
respectively. Apart from relatively small hands, no 
dysmorphisms were noticed. Psychiatric examination 
disclosed an anxious and dependent attitude with lack 
of social initiative without, however, any signs of major 
psychiatric symptoms. Neuropsychological assessment 
disclosed mild intellectual disability (WAIS-III Total, 
Verbal and Performal IQ: 51, 48 and 61, respectively) 
with enhanced distractibility and lowered speed of 
information processing. Cytogenetic analysis revealed 
no abnormalities and Fragile-X syndrome was excluded. 
Social supportive therapy was advised without the 
need for neuropsychiatric follow-up. However, five 
years later, after her mother had deceased, she was 
referred to a neurologist because of persistent attention 
and memory problems. Apart from some minor 
periventricular white matter lesions (detected with MRI 
scanning), no neurological abnormalities were found 
and psychotherapeutic interventions were started.
The patient was referred again because of suspected 
gradual decline of neurocognitive functioning as 
well as complaints about increased anxiety levels. 
Intellectual capacities were similar to the former 
measurement (WAIS-IV Total, Verbal and Performal 
IQ: 53, 51 and 72, respectively). As to neurocognition, 
performance levels were generally comparable to 
those found ten years before except for speed of 
information processing and executive functioning 
which were both lowered. In addition, some indication 
for socio-emotional impairment was found. Apart 
from minor signs of distress, psychiatric symptoms 
could not be ascertained. MRI scanning of the brain 
revealed no changes as compared to six years before 
and was considered normal. Genome wide CytoScan 
HD array analysis showed a paternally inherited 
205 kb gain in 22q11.1 and a de novo, interstitial 
duplication of 1.48 Mb in 17q12 encompassing 24 
genes (arr[hg19]17q12(34,823,616-36,307,774)x3 
dn,22q11.1(17,624,770-17,831,814)x3 pat; Figure 
2). The duplication in 17q12 is a known recurrent 
microduplication that is associated with the so-called 
17q12 duplication syndrome (OMIM #614526) which 
is predominantly characterized by mild to moderate 
intellectual disability.
All reported complaints about cognitive functioning 
and recurrent anxieties could be emanated from an 
enhanced susceptibility to context-related socio-
emotional overestimation. Therefore, a more structured 
environmental approach was recommended with 
periodic re-evaluation of cognitive functioning. No 
further psychopharmacological or psychosocial 
interventions were indicated. 
Discussion
In this paper, two adult female patients with mild 
Clinical reports
Patient A is a 39-year-old female, prematurely born 
from non-consanguineous parents with a birth weight 
of 1,380g. Apart from diabetes mellitus type II and 
cardiovascular problems in her mother’s family, there is 
no load with intellectual disability or neuropsychiatric 
diseases. She had one older brother who died at the age 
of 15 years in a serious traffic accident. When the patient 
was two years old she nearly drowned. Developmental 
milestones were all delayed and the patient tended to 
avoid social contact. After having followed special 
education, she completed domestic science school 
after which she was employed for unskilled working 
activities. Over subsequent years, the patient developed, 
contingent upon environmental demands, periods with 
pseudo-hallucinatory auditory experiences, anxieties, 
irritability and lowering of mood as well as inactivity 
and withdrawal behaviours. At the age of 23 years, she 
had a first contact with social psychiatry services and 
four years later she was hospitalized for a short period. 
A diagnosis of depression was made and treatment 
with citalopram was started, later in combination with 
quetiapine. Thereafter, she moved to a sheltered home 
facility and continued her work.
The patient was referred by her general practitioner 
to the specialized outpatient department for 
neuropsychiatry for re-evaluation of mood complaints 
in the context of her delayed development.
At examination, a female obese patient was seen 
with large ears and lobules, deep set eyes and colu-
mella below alae nasi, but no major dysmorphisms. 
Height, weight and head circumference were 174cm 
(+0.5 SD), 124kg (>>+2 SD) and 55.5cm (0 SD), re-
spectively. Neuropsychiatric and somatic/neurological 
examination disclosed a tendency to referential think-
ing, but no signs of major depression or other abnormal 
findings. Haematological and biochemical parameters 
including FT4 were all within normal range. Extensive 
neuropsychological testing revealed mild intellectual 
disability (WAIS-IV Total IQ: 54) with lowered ver-
bal comprehension and working memory, the latter at-
tenuating particularly verbal learning capacities. Social 
cognitive functioning, including Theory of Mind, was 
undisturbed albeit with diminished (facial) expression 
of heightened stress levels. This configuration of cogni-
tive and neuropsychiatric characteristics enhances the 
risk for overestimation presenting with reactive depres-
sive signs. 
Subsequent genome wide analysis on DNA from 
peripheral blood using a CytoScanHD array platform 
(Affymetrix, Santa Clara, CA, USA) demonstrated a 
de novo interstitial deletion of 2.05 Mb in 7p21.1p15.3 
(arr[hg19] 7p21.1p15.3(20,788,314-22,837,872)x1~2 
dn). The deletion, comprising 12 genes, appeared to 
be present in ~50% of the cells (cross validated and 
confirmed in DNA from buccal swab cells) and was 
considered to be implicated in the developmental 
problems (Figure 1).
Because no diagnosis of major depression could be 
established and since the use of quetiapine for many 
years had resulted in marked obesity, the patient was 
advised to taper off gradually both citalopram (40mg 
daily) and quetiapine (300mg daily), guided by her own 
general practitioner. Instead, a very structured living and 
working environment avoiding unpredictable events 
was recommended in order to avoid social interaction 
bound overestimation.
Patient B is a 46-year-old female who was referred 
for the first time, aged 36 years, to the specialized 
outpatient department for neuropsychiatry by the 
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Figure 1. A.Array plot of chromosome 7 of patient A with a de novo, mosaic, interstitial deletion of 2.05 Mb in 
7p21.1p15.3. The single horizontal line represents the probe signal values, with n=2 for a normal copy number. 
The genotype information is represented below this single line by the so-called B-Allele Frequency, with three 
combinations possible in case of n=2 (AA, BA or BB) and two combinations for n=1 (A or B), if there is a deletion. 
In case of a mosaic loss there will be a mixture of cells with and without loss of the 7p21.1p15.3 allele resulting in 
four possible combinations (BB, BA, AB or AA). The plot in blue shows the array findings in DNA from buccal swab 
cells and the plot in pink the array findings in DNA from peripheral blood. B. Screen shot of the UCSC genome 
browser (https://genome.ucsc.edu) of the aberrant 7p21.1p15.3 region encompassing 12 protein-coding genes. The 
probe coverage on the CytoScanHD array platform and the presence of repeat sequences are indicated in the lower 
part of the figure
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Figure 2. A. Array plot of chromosome 17 of patient B with a de novo, interstitial gain of 1.48 Mb in 17q12. 
The single horizontal line represents the probe signal values, with n=2 for a normal copy number. The genotype 
information is represented below this single line by the so-called B-Allele Frequency, with three combinations 
possible in case of n=2 (AA, BA or BB), two combinations for n=1 (A or B), if there is a deletion, and four 
combinations in case of a gain, n=3 (AAA, AAB, ABB or BBB). 
B. Screen shot of the UCSC genome browser (https://genome.ucsc.edu) of the aberrant 17q12 region encompassing 
24 protein-coding genes. The probe coverage on the CytoScanHD array platform and the presence of repeat 
sequences are indicated in the lower part of the figureA
B
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intellectual disability and relatively adequate social 
participation are described. In both, de novo CNVs 
were demonstrated to be causatively implicated in their 
developmental delay. In patient A, a mosaic interstitial 
deletion in 7p21.1p15.3 was detected while in patient 
B a 17q12 microduplication was established. In both 
patients, referral was initiated because of suspected 
cognitive decline and/or psychiatric symptoms from 
the affect domain. 
With respect to the 7p deletion, no deletions of 
comparable size have been reported so far. There are 
only a few patients described in the literature and 
a mere dozen patients registered in clinical genetic 
databases such as ECARUCA (www.ecaruca.net) and 
DECIPHER (https://decipher.sanger.ac.uk). However, 
these concern patients with significantly larger deletions 
that are associated with severe intellectual disability, 
marked dysmorphisms and somatic anomalies (Chotai 
et al. 1994, Shimada et al. 2013). 
The 17q12 duplication syndrome is associated with 
a highly variable degree of intellectual disability and, 
in most cases, with neurological and somatic disorders, 
such as seizures and renal abnormalities (Mefford et al. 
2007, Nagamani et al. 2010, Caselli et al. 2010, Faguer 
et al. 2011, Bierhals et al. 2013). 
As to patient A, more than 15 years prior to 
referral, a diagnosis of major depression was made 
after which she underwent a form of psychotherapy 
focused on anxious cognitions. In addition, she was 
treated over a long period of time with psychotropics. 
The psychotherapeutic intervention did not attenuate 
her anxious feelings and affective dysregulations and 
was therefore discontinued. Psychopharmacological 
treatment lacked any effect and resulted in morbid 
obesity (BMI: 41). Recurrent complaints about 
cognitive functioning brought patient B under the 
attention of a neurologist who did not detect any 
abnormalities and forwarded her to a psychotherapist to 
cope with anxieties and feelings of bereavement related 
to her mother’s death. No improvement was achieved, 
instead, symptoms of distress and memory complaints 
intensified. In both patients, personalized contextual 
measures with increased staff involvement resulted in a 
reduction of complaints and amelioration of behaviour.
In conclusion, as can be inferred from the above, 
the absence of notable facial dysmorphisms or somatic 
abnormalities often does not signal the clinician to 
initiate essential etiological examinations. Likewise, 
such a presentation may also easily obscure the 
presence of (mild) intellectual disability which, in turn, 
evokes psychiatric and neurologic misdiagnoses with 
a subsequent cascade of unnecessary, ineffective and 
sometimes harmful treatment programs.
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